Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Abstract
The surface receptor MET is highly expressed on primary uveal melanoma; MET inhibitors demonstrated early clinical signals of efficacy in slowing uveal melanoma growth. The primary objective of our study was to compare the progression-free survival rate at 4 months (PFS4) of patients with uveal melanoma treated with cabozantinib or chemotherapy.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 14, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-1223
Entities
People
- Brian W. Labadie
- Bruno R. Bastos
- Carrie A. Strand
- Daniel J. Olson
- David Hogg
- Gary K. Schwartz
- Jacob B. Allred
- Jason J Luke
- Marcus O Butler
- Pamela N. Munster
- Riyue Bao
- Timothy Carll
- Yuanyuan Zha
Organizations
- Herbert Irving Comprehensive Cancer Center
- Mayo Clinic
- National Cancer Institute
- University of Chicago